Day: July 26, 2024

PRINCETON JUNCTION, N.J., July 26, 2024 (GLOBE NEWSWIRE) — MISTRAS Group, Inc. (MG: NYSE) has scheduled a conference call for Thursday, August 1, 2024 at 9:00 am Eastern Time to discuss its results for the second quarter of 2024. A press release with the second quarter results will be issued after the close of market on Wednesday, July 31, 2024. To listen to the live webcast of the conference call, visit the Investor Relations section of MISTRAS Group’s website at www.mistrasgroup.com. Individuals wishing to participate in the live question and answer session may pre-register at: https://register.vevent.com/register/BI05aef0d9604542e897138e5abb38ad5a. Following the conference call, an archived webcast of the call will be available for one year by visiting the Investor Relations section of MISTRAS Group’s website. About MISTRAS...

Deposit Expansion, Market Share Growth, Asset Quality LYNCHBURG, Va., July 26, 2024 (GLOBE NEWSWIRE) — Bank of the James Financial Group, Inc. (the “Company”) (NASDAQ:BOTJ), the parent company of Bank of the James (the “Bank”), a full-service commercial and retail bank, and Pettyjohn, Wood & White, Inc. (“PWW”), an SEC-registered investment advisor, today announced unaudited results of operations for the three month and six month periods ended June 30, 2024. The Bank serves Region 2000 (the greater Lynchburg MSA) and the Blacksburg, Buchanan, Charlottesville, Harrisonburg, Lexington, Nellysford, Roanoke, and Wytheville, Virginia markets. Net income for the three months ended June 30, 2024 was $2.15 million or $0.47 per basic and diluted share compared with $2.53 million or $0.56 per basic and diluted share for the three months...

Additional $4 Million and Extension of Maturity on Existing $7.5 Million Facility NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) — Roadzen Inc. (Nasdaq: RDZN) (“Roadzen” or the “Company”), a global leader in AI at the convergence of insurance and mobility, today announced that it secured an extension of the maturity date and an additional $4.0 million of capital from Mizuho Securities USA LLC, a leading global investment bank and securities firm. The amended facility increases the loan from $7.5 million to $11.5 million of 15% senior secured notes, without any additional warrants, and extends the maturity date to December 31, 2024. “We greatly appreciate Mizuho’s continued belief in our vision. This extension and facility increase, combined with management’s recent debt-to-equity exchange, advances our continuing...

Sunstone IV hf. announces change of name to Míla Holding hf. Shareholders’ of Sunstone IV hf., reg. no. 620921-2540 (the “Company”) approved on 20 June 2024 to change the Company’s name from Sunstone IV hf. to Míla Holding hf. The name change was registered in the Icelandic Company Registry (Icel. Fyrirtækjaskrá) on 24 July 2024. The identities of the Company’s issued securities did not change. For more information please contact: Inga Helga HalldórudóttirCompliance officerMíla Holding hf. ingah@mila.isAttachment20240625_GNW – Name Change -FINAL-

July 26, 2024 News Release BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo ADLM 2024 Conference – Chicago, July 26, 2024 – BioPorto Diagnostics, a company specializing in in vitro diagnostics with an emphasis on the early detection of Acute Kidney Injury (AKI), will be participating in the Association for Diagnostics and Laboratory Medicine (ADLM) 2024 clinical lab expo. BioPorto will feature its FDA-cleared product designed for pediatric AKI risk assessment, ProNephro AKI™ (NGAL), at this conference. ProNephro AKI is based on the NGAL (neutrophil gelatinase-associated lipocalin) biomarker and is the first FDA-cleared assay of its kind for the pediatric population. The authorization by FDA provides healthcare professionals with an additional tool for evaluating the risk of AKI. ADLM 2024 (formerly...

New York, July 26, 2024 (GLOBE NEWSWIRE) — Value Line, Inc., (NASDAQ: VALU) reported results for the fiscal year ended April 30, 2024. During the twelve months ended April 30, 2024, the Company’s net income of $19,016,000, or $2.02 per share, was 5.2% above net income of $18,069,000, or $1.91 per share, for the twelve months ended April 30, 2023. The Company’s receipts of $13,282,000 from its non-voting revenues interest in EAM and non-voting profits interest in EAM increased $2,151,000 or 19.3% above the prior fiscal year. For the twelve months ended April 30, 2024, excluding restructuring costs related to outsourcing to two U.S. based companies of certain fulfillment and distribution operations, operating expenses decreased approximately 1.0% below those during the twelve months ended April 30, 2023. During the three months ended...

SHANGHAI, July 26, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary TopAlliance Biosciences Inc. (TopAlliance Biosciences), announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for the marketing authorization application (MAA) for toripalimab (European trade name: LOQTORZI®). The CHMP recommends approval for toripalimab for two indications:Toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal...